Melanoma
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Clinical Insights
COVID-19 prompts ‘democratization’ of cancer trials
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.
From the Journals
Hair dye and cancer study ‘offers some reassurance’
From the Journals
Durable response 5 years after adjuvant combo in melanoma
Plateaus observed with relapse and distant metastasis-free survival suggest that true disease cures are being achieved with treatment.
From the Journals
Fatal pediatric melanomas diverse in presentation
One-fourth of fatal pediatric melanomas arose in association with congenital melanocytic nevi.
Latest News
Melanoma experts say ‘no’ to routine gene profile testing
This test is not endorsed by the American Academy of Dermatology or National Comprehensive Cancer Network outside of studies.
Conference Coverage
VTE, sepsis risk increased among COVID-19 patients with cancer
Cancer patients had significantly lower hemoglobin levels, platelet counts, and red and white blood cell counts.
From the Journals
Immunotherapy should not be withheld because of sex, age, or PS
From the Journals
Aspirin may accelerate cancer progression in older adults
From the Journals
Age, smoking among leading cancer risk factors for SLE patients
While older age was a risk factor for both breast and nonmelanoma skin cancers, use of antimalarial drugs lowered the risk of both.